Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: Experience in an Italian region

F. Albertoni, A. Battilomo, V. Di Nardo, E. Franco, G. Ippolito, G. Marinucci, C. A. Perucci, N. Petrosillo, L. Sommella, D. Abdelahad, A. Amici, G. Angeloni, P. Angeloni, C. Borgia, E. Carbone, M. G. Carbone, P. Casale, G. Catania, M. A. Cioccetti

Research output: Contribution to journalArticlepeer-review

Abstract

In 1985-1986, 634 adult dialysis patients were tested prior to hepatitis B vaccination, representing 40% of the total patients in Latium, an Italian region. HBsAg and anti-HBs prevalences were 7.1 and 36.0%, respectively. Merck, Sharp and Dohme (MSD) and Pasteur plasma-derived vaccines were randomly allocated to the 44 dialysis units. An anti-HBs response ≥ 10 IU/l was elicited in 58.5% of 236 subjects tested at 6 months, 63.4% MSD and 52.4% Pasteur (p n.s.). The relatively low response to the vaccine in this high-risk group stresses the need to improve the efficacy of the vaccination and to maintain policies of environmental control.

Original languageEnglish
Pages (from-to)180-183
Number of pages4
JournalNephron
Volume58
Issue number2
Publication statusPublished - 1991

Keywords

  • dialysis
  • hepatitis B
  • regional evaluation
  • vaccination program

ASJC Scopus subject areas

  • Nephrology

Fingerprint

Dive into the research topics of 'Evaluation of a region-wide hepatitis B vaccination program in dialysis patients: Experience in an Italian region'. Together they form a unique fingerprint.

Cite this